Sterling Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Sterling Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.3K	Buy	1,221 +21	+2%	+$200	﹤0.01%	2359
2025 Q4	$14.6K	Buy	1,200 +859	+252%	+$10.4K	﹤0.01%	2411
2025 Q3	$3.99K	Buy	341 +1	+0.3%	+$12	﹤0.01%	2833
2025 Q2	$3.15K	Buy	340 +166	+95%	+$1.3K	﹤0.01%	2760
2025 Q1	$1.27K	Buy	174 +16	+10%	+$123	﹤0.01%	2732
2024 Q4	$1.35K	Hold	158	–	–	﹤0.01%	2875
2024 Q3	$1.38K	Buy	+158	New	+$1.3K	﹤0.01%	2374

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Sterling Capital Management's OCUL Position: Q1 2026 in Review

Sterling Capital Management increased its Ocular Therapeutix (OCUL) stake by 1.8% in Q1 2026, buying an estimated $200 and bringing the position to 1,221 shares worth $10.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2359.

Sterling Capital Management first reported a position in OCUL in Q3 2024 and has held it in 7 quarters since. The position peaked at $14.6K in Q4 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Sterling Capital Management held 1,221 shares of Ocular Therapeutix worth $10.3K as of Q1 2026.
Sterling Capital Management bought 21 Ocular Therapeutix shares in Q1 2026, an estimated $200.
Ocular Therapeutix made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2359 holding.
Sterling Capital Management first reported a position in Ocular Therapeutix in Q3 2024 and has held it in 7 quarters since.
Sterling Capital Management's Ocular Therapeutix position peaked at $14.6K in Q4 2025.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.